Search
for
Sort by
Research 211–240 of 259
- Suspected adverse reactions to medications and food supplements containing <i>Serenoa repens</i>: A worldwide analysis of pharmacovigilance and phytovigilance spontaneous reports
- Clinical Efficacy of Topical or Oral Soy Supplementation in Dermatology: A Systematic Review
- Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System
- A comprehensive genome-wide analysis for signatures of selection in goat (genus Capra) revealed new candidate genes for environmental adaptation and productive traits
- Understanding sex and gender disparities in COVID-19 mortality: a narrative review beyond biology
- Efficacy of exosomes in acute kidney injury treatment and the associated mechanism (Review)
- The first 20 years of skin of color dermatology: An era of advancements in skin, hair, and nail disorders
- The Potential Reversible Transition between Stem Cells and Transient-Amplifying Cells: The Limbal Epithelial Stem Cell Perspective
- Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
- Assessing the Quality and Reliability of Rheumatoid Arthritis Exercise Videos on TikTok and YouTube
- An ERK-dependent molecular switch antagonizes fibrosis and promotes regeneration in spiny mice ( <i>Acomys</i> )
- Managing Dermatologic Effects of Gender-Affirming Therapy in Transgender Adolescents
- The Multiple Consequences of Obesity
- Pharmacovigilance profiles of three generations of mineralocorticoid receptor antagonists and network toxicology analysis
- Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions—A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data
- Research Progress on the Immunomodulatory Effects by Dang Gui (Radix Angelica sinensis) and Its Active Chemical Components
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Medical Technologies: Pharmaceutical Cosmetology, Cosmeceuticals – Opportunities and Limitations
- Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
- Innovations in skin microphysiological systems for nonclinical testing and FDA modernization
- Overcoming Curcumin's Limitations: Synthetic Derivatives in Diabetes and Cancer Management
- Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
- Integrated Meta-Analysis of Scalp Transcriptomics and Serum Proteomics Defines Alopecia Areata Subtypes and Core Disease Pathways
- Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025
- Overlapping features of atopic dermatitis and alopecia areata: from pathogenesis to treatment
- Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications
- Exploring the molecular mechanism of Polygonum multiflorum in treating androgenic alopecia based on the methods of bioinformatics and molecular docking
- Exploring lncRNA-Mediated Mechanisms in Muscle Regulation and Their Implications for Duchenne Muscular Dystrophy
- Transcriptomic Analysis of Skin Tissue Reveals Molecular Mechanisms of Thermal Adaptation in Cold-Exposed Lambs
- Unique Circulating MicroRNA Signatures Distinguish Severe Alopecia Areata from Other Inflammatory Skin Diseases